Characterization of AβpN3 deposition in the brains of dogs of various ages and other animal species

Amyloid

Volumn 18, Issue 2, 2011, Pages 63-71

  Chambers, James K ^a   Mutsuga, Mayu ^a   Uchida, Kazuyuki ^a   Nakayama, Hiroyuki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

AbpN3; aging; Alzheimer's disease; Canine

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN N1; AMYLOID BETA PROTEIN N3; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ANIMAL TISSUE; ARTICLE; BEAR; BIRD; BRAIN REGION; CAT; DISEASE MODEL; DOG; FEMALE; HUMAN; HUMAN TISSUE; MACACA; MALE; MICROANGIOPATHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; SENESCENCE; SENILE PLAQUE; VASCULAR AMYLOIDOSIS;

AGED; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BIRDS; BRAIN; CATS; CEREBRAL AMYLOID ANGIOPATHY; DOGS; FEMALE; HUMANS; MACACA; MALE; MICE; MICE, TRANSGENIC; PLAQUE, AMYLOID; RETROSPECTIVE STUDIES; URSIDAE;

EID: 79955801619     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2011.570385     Document Type: Article

References (70)

1. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985;82:4245-4249. (Pubitemid 15053619)
2. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991;6:487-498.
3. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008; 65:1509-1517.
4. Armstrong RA, Cairns NJ, Myers D, Smith CU, Lantos PL, Rossor MN. A comparison of beta-amyloid deposition in the medial temporal lobe in sporadic Alzheimer's disease, Down's syndrome and normal elderly brains. Neurodegeneration 1996;5:35-41. (Pubitemid 26132265)
5. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, et al. Mild cognitive impairment. Lancet 2006;367:1262-1270.
6. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: Clinical characteriza-tion and outcome. Arch Neurol 1999;56:303-308. (Pubitemid 29120227)
7. Czasch S, Paul S, Baumgartner W. A comparison of immunohistochemical and silver staining methods for the detection of diffuse plaques in the aged canine brain. Neurobiol Aging 2006;27:293-305. (Pubitemid 43038554)
8. Shimada A, Kuwamura M, Umemura T, Takada K, Ohama E, Itakura C. Modified bielschowsky and immunohistochem-ical studies on senile plaques in aged dogs. Neurosci Lett 1991;129:25-28.
9. Uchida K, Nakayama H, Goto N. Pathological studies on cerebral amyloid angiopathy, senile plaques and amyloid deposition in visceral organs in aged dogs. J Vet Med Sci 1991;53:1037-1042.
10. Brellou G, Vlemmas I, Lekkas S, Papaioannou N. Immuno-histochemical investigation of amyloid beta-protein (abeta) in the brain of aged cats. Histol Histopathol 2005;20:725-731. (Pubitemid 40932590)
11. Nakamura S, Nakayama H, Kiatipattanasakul W, Uetsuka K, Uchida K, Goto N. Senile plaques in very aged cats. Acta Neuropathol 1996;91:437-439. (Pubitemid 26088982)
12. Nakamura S, Nakayama H, Goto N, Ono-Ochikubo F, Sakakibara I, Yoshikawa Y. Histopathological studies on senile plaques and cerebral amyloid angiopathy in aged cynomolgus monkeys. Exp Anim 1995;43:711-718.
13. Struble RG, Price DL Jr, Cork LC, Price DL. Senile plaques in cortex of aged normal monkeys. Brain Res 1985;361:267-275. (Pubitemid 16185363)
14. Walker LC, Masters C, Beyreuther K, Price DL. Amyloid in the brains of aged squirrel monkeys. Acta Neuropathol 1990;80:381-387. (Pubitemid 20255761)
15. Wisniewski HM, Ghetti B, Terry RD. Neuritic (senile) plaques and filamentous changes in aged rhesus monkeys. J Neuropathol Exp Neurol 1973;32:566-584.
16. Cork LC, Powers RE, Selkoe DJ, Davies P, Geyer JJ, Price DL. Neurofibrillary tangles and senile plaques in aged bears. J Neuropathol Exp Neurol 1988;47:629-641.
17. Uchida K, Yoshino T, Yamaguchi R, Tateyama S, Kimoto Y, Nakayama H, Goto N. Senile plaques and other senile changes in the brain of an aged american black bear. Vet Pathol 1995;32:412-414.
18. Roertgen KE, Parisi JE, Clark HB, Barnes DL, O'Brien TD, Johnson KH. A beta-associated cerebral angiopathy and senile plaques with neurofibrillary tangles and cerebral hemorrhage in an aged wolverine (gulo gulo). Neurobiol Aging 1996;17: 243-247. (Pubitemid 26167635)
19. Nakamura S, Nakayama H, Uetsuka K, Sasaki N, Uchida K, Goto N. Senile plaques in an aged two-humped (bactrian) camel (camelus bactrianus). Acta Neuropathol 1995;90:415-418.
20. Nakayama H, Katayama K, Ikawa A, Miyawaki K, Shinozuka J, Uetsuka K, Nakamura S, Kimura N, Yoshikawa Y, Doi K. Cerebral amyloid angiopathy in an aged great spotted wood-pecker (picoides major). Neurobiol Aging 1999;20:53-56. (Pubitemid 29352363)
21. Papaioannou N, Tooten PCJ, van Ederen AM, Bohl JRE, Rofina J, Tsangaris T, Gruys E. Immunohistochemical investigation of the brain of aged dogs. I. Detection of neurofibrillary tangles and and of 4-hydroxynonenal protein, an oxidative damage product, in senile plaques. Amyloid 2001;8:11-21. (Pubitemid 32210176)
22. Rofina J, van Andel I, van Ederen AM, Papaioannou N, Yamaguchi H, Gruys E. Canine counterpart of senile dementia of the Alzheimer type: amyloid plaques near capillaries but lack of spatial relationship with activated microglia and macrophages. Amyloid 2003;10:86-96. (Pubitemid 36936539)
23. Rofina JE, Singh K, Skoumalova-Vesela A, van Ederen AM, van Asten AJAM, Wilhelm J, Gruys E. Histochemical accumulation of oxidative damage products is associated with Alzheimer-like pathology in the canine. Amyloid 2004;11:90-100. (Pubitemid 39222405)
24. Janus C, Westaway D. Transgenic mouse models of Alzhei¬mer's disease. Physiol Behav 2001;73:873-886. (Pubitemid 32885575)
25. Wisniewski T, Sigurdsson EM. Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochim Biophys Acta 2010;1802:847-859.
26. Philipson O, Lord A, Gumucio A, O'Callaghan P, Lannfelt L, Nilsson LN. Animal models of amyloid-beta-related pathol-ogies in Alzheimer's disease. FEBS J 2010;277:1389-1409.
27. Sarasa M, Pesini P. Natural non-trasgenic animal models for research in Alzheimer's disease. Curr Alzheimer Res 2009; 6:171-178.
28. Head E, McCleary R, Hahn FF, Milgram NW, Cotman CW. Region-specific age at onset of beta-amyloid in dogs. Neurobiol Aging 2000;21:89-96. (Pubitemid 30224790)
29. Cummings BJ, Head E, Ruehl W, Milgram NW, Cotman CW. The canine as an animal model of human aging and dementia. Neurobiol Aging 1996;17:259-268. (Pubitemid 26167637)
30. Nakayama H, Uchida K, Doi K. A comparative study of age-related brain pathology-are neurodegenerative diseases present in nonhuman animals? Med Hypotheses 2004;63:198-202. (Pubitemid 38968715)
31. Pugliese M, Mascort J, Mahy N, Ferrer I. Diffuse beta-amyloid plaques and hyperphosphorylated tau are unrelated processes in aged dogs with behavioral deficits. Acta Neuropathol 2006;112:175-183.
32. Saido TC, Yamao-Harigaya W, Iwatsubo T, Kawashima S. Amino-and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci Lett 1996;215: 173-176. (Pubitemid 26323454)
33. Fukumoto H, Asami-Odaka A, Suzuki N, Shimada H, Ihara Y, Iwatsubo T. Amyloid beta protein deposition in normal aging has the same characteristics as that in Alzheimer's disease. predominance of A beta 42(43) and association of A beta 40 with cored plaques. Am J Pathol 1996;148:259-265. (Pubitemid 26019660)
34. Piccini A, Russo C, Gliozzi A, Relini A, Vitali A, Borghi R, Giliberto L, Armirotti A, D'Arrigo C, Bachi A, et al. Beta-amyloid is different in normal aging and in Alzheimer disease. J Biol Chem 2005;280:34186-34192. (Pubitemid 41443143)
35. Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, Holzer M, Hutter-Paier B, Prokesch M, Windisch M, et al. Glutaminyl cyclase inhibition attenuates pyroglu-tamate abeta and Alzheimer's disease-like pathology. Nat Med 2008;14:1106-1111.
36. Gunn AP, Masters CL, Cherny RA. Pyroglutamate-abeta: Role in the natural history of Alzheimer's disease. Int J Biochem Cell Biol 2010;42:1915-1918.
37. Marcello A, Wirths O, Schneider-Axmann T, Degerman-Gunnarsson M, Lannfelt L, Bayer TA. Reduced levels of IgM autoantibodies against N-truncated pyroglutamate abeta in plasma of patients with Alzheimer's disease Neurobiol Aging, in press
38. Reeves RH. Down's syndrome. A complicated genetic insult. Lancet 2001;358:Suppl:S23.
39. Russo C, Saido TC, DeBusk LM, Tabaton M, Gambetti P, Teller JK. Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer's disease and down's syndrome brains. FEBS Lett 1997;409:411-416. (Pubitemid 27285896)
40. Yoshino T, Uchida K, Tateyama S, Yamaguchi R, Nakayama H, Goto N. A retrospective study of canine senile plaques and cerebral amyloid angiopathy. Vet Pathol 1996;33:230-234. (Pubitemid 126484266)
41. Portelius E, Bogdanovic N, Gustavsson MK, Volkmann I, Brinkmalm G, Zetterberg H, Winblad B, Blennow K. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol 2010;120:185-193.
42. Tekirian TL. Commentary: Abeta N-terminal isoforms: Critical contributors in the course of AD pathophysiology. J Alzheimers Dis 2001;3:241-248. (Pubitemid 32566523)
43. Johnstone EM, Chaney MO, Norris FH, Pascual R, Little SP. Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis. Brain Res Mol Brain Res 1991;10:299-305.
44. Selkoe DJ, Bell DS, Podlisny MB, Price DL, Cork LC. Conservation of brain amyloid proteins in aged mammals and humans with Alzheimer's disease. Science 1987;235:873-877. (Pubitemid 17019123)
45. Schilling S, Appl T, Hoffmann T, Cynis H, Schulz K, Jagla W, Friedrich D, Wermann M, Buchholz M, Heiser U, et al. Inhibition of glutaminyl cyclase prevents pGlu-abeta forma¬tion after intracortical/hippocampal microinjection in vivo/in situ. J Neurochem 2008;106:1225-1236.
46. Pohl T, Zimmer M, Mugele K, Spiess J. Primary structure and functional expression of a glutaminyl cyclase. Proc Natl Acad Sci USA 1991;88:10059-10063. (Pubitemid 21915775)
47. Schilling S, Wasternack C, Demuth HU. Glutaminyl cyclases from animals and plants: A case of functionally convergent protein evolution. Biol Chem 2008;389: 983-991.
48. Stephan A, Wermann M, von Bohlen A, Koch B, Cynis H, Demuth HU, Schilling S. Mammalian glutaminyl cyclases and their isoenzymes have identical enzymatic characteristics. FEBS J 2009;276:6522-6536.
49. Sykes PA, Watson SJ, Temple JS, Bateman RC Jr.Evidence for tissue-specific forms of glutaminyl cyclase. FEBS Lett 1999;455:159-161. (Pubitemid 29322801)
50. Hartig W, Goldhammer S, Bauer U, Wegner F, Wirths O, Bayer TA, Grosche J. Concomitant detection of beta-amyloid peptides with N-terminal truncation and different C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple transgenic mice. J Chem Neuroanat 2010;40:82-92.
51. He W, Barrow CJ. The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta. Biochemistry 1999;38:10871-10877.
52. Sanders HM, Lust R, Teller JK. Amyloid-beta peptide Abetap3-42 affects early aggregation of full-length Abeta1-42. Peptides 2009;30:849-854.
53. Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 2004;5:677-685. (Pubitemid 39150139)
54. Solomon B. Alzheimer's disease and immunotherapy. Curr Alzheimer Res 2004;1:149-163.
55. Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, et al. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathol-ogy. Proc Natl Acad Sci USA 2003;100:2023-2028. (Pubitemid 36254567)
56. Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci USA 1997;94:4109-4112. (Pubitemid 27180507)
57. Acero G, Manoutcharian K, Vasilevko V, Munguia ME, Govezensky T, Coronas G, Luz-Madrigal A, Cribbs DH, Gevorkian G. Immunodominant epitope and properties of pyroglutamate-modified abeta-specific antibodies produced in rabbits. J Neuroimmunol 2009;213:39-46.
58. Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, Rajadas J, Zhang H, Tomooka B, Robinson WH, et al. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci USA 2009;106:12145-12150.
59. Frenkel D, Katz O, Solomon B. Immunization against Alzheimer's beta-amyloid plaques via EFRH phage adminis-tration. Proc Natl Acad Sci USA 2000;97:11455-11459.
60. Head E, Pop V, Vasilevko V, Hill M, Saing T, Sarsoza F, Nistor M, Christie LA, Milton S, Glabe C, et al. A two-year study with fibrillar beta-amyloid (abeta) immunization in aged canines: Effects on cognitive function and brain abeta. J Neurosci 2008;28:3555-3566.
61. Bernedo V, Insua D, Suarez ML, Santamarina G, Sarasa M, Pesini P. Beta-amyloid cortical deposits are accompanied by the loss of serotonergic neurons in the dog. J Comp Neurol 2009;513:417-429.
62. Cummings BJ, Head E, Afagh AJ, Milgram NW, Cotman CW. Beta-amyloid accumulation correlates with cognitive dysfunction in the aged canine. Neurobiol Learn Mem 1996; 66:11-23. (Pubitemid 26195731)
63. Head E, Callahan H, Muggenburg BA, Cotman CW, Milgram NW. Visual-discrimination learning ability and beta-amyloid accumulation in the dog. Neurobiol Aging 1998;19:415-425. (Pubitemid 29065491)
64. Rofina JE, van Ederen AM, Toussaint MJM, Secreve M, van der Spek A, van der Meer I, van Eerdenburg FJCM, Gruys E. Cognitive disturbances in old dogs suffering from the canine counterpart of Alzheimer's disease. Brain Res 2006;1069: 216-226. (Pubitemid 43145916)
65. Tapp PD, Siwak CT, Estrada J, Head E, Muggenburg BA, Cotman CW, Milgram NW. Size and reversal learning in the beagle dog as a measure of executive function and inhibitory control in aging. Learn Mem 2003;10:64-73. (Pubitemid 36177022)
66. Tapp PD, Siwak CT, Estrada J, Holowachuk D, Milgram NW. Effects of age on measures of complex working memory span in the beagle dog (canis familiaris) using two versions of a spatial list learning paradigm. Learn Mem 2003;10:148-160. (Pubitemid 36418725)
67. Russo C, Violani E, Salis S, Venezia V, Dolcini V, Damonte G, Benatti U, D'Arrigo C, Patrone E, Carlo P, et al. Pyroglutamate-modified amyloid beta-peptides-AbetaN3 (pE)-strongly affect cultured neuron and astrocyte survival. J Neurochem 2002;82:1480-1489.
68. Wirths O, Breyhan H, Cynis H, Schilling S, Demuth HU, Bayer TA. Intraneuronal pyroglutamate-abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol 2009;118:487-496.
69. Weller RO, Massey A, Newman TA, Hutchings M, Kuo YM, Roher AE. Cerebral amyloid angiopathy: Amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am J Pathol 1998;153: 725-733. (Pubitemid 28419027)
70. Vanderstichele H, De Meyer G, Andreasen N, Kostanjevecki V, Wallin A, Olsson A, Blennow K, Vanmechelen E. Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. Clin Chem 2005;51:1650-1660. (Pubitemid 41233100)